World Journal of Gastroenterology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

209

HTML

2340

Figures (1-1)

279

Tables (1-1)

267

Sum=3095

Publishing Process of This Article

Item

Count

Browse

181

Download

353

Sum=534

Apr 6, 2024 (publication date) through Mar 13, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef

For:	Meštrović A, Kumric M, Bozic J. Discontinuation of therapy in inflammatory bowel disease: Current views. World J Clin Cases 2024; 12(10): 1718-1727 [PMID: 38660068 DOI: 10.12998/wjcc.v12.i10.1718]
URL:	https://www.wjgnet.com/1007-9327/full/v12/i10/1718.htm

Number	Citing Articles
1	Kazuo Yashima, Hiroki Kurumi, Naoyuki Yamaguchi, Hajime Isomoto. Progressing advanced therapies for inflammatory bowel disease: Current status including dual biologic therapy and discontinuation of biologics. Expert Review of Gastroenterology & Hepatology 2025; 19(3): 291 doi: 10.1080/17474124.2025.2469832
2	Ya-Xiong Guo, Xiong Yan, Xu-Chang Liu, Yu-Xiang Liu, Chun Liu. Artificial intelligence-driven strategies for managing renal and urinary complications in inflammatory bowel disease. World Journal of Nephrology 2025; 14(1): 100825 doi: 10.5527/wjn.v14.i1.100825 Abstract(139) \| Core Tip(146) \| Full Article(HTML)(359) \| Full Article with Cover (PDF)-676K(22) \| Audio-180K(6) \| Peer-Review Report-176K(25) \| Answering Reviewers-141K(16) \| Full Article (PDF)-399K(29) \| Full Article (XML)-102K(23) \| Times Cited (0) \| Total Visits (904) \| Open
3	Alessandro Massano, Edoardo Vincenzo Savarino, Simone Saibeni, Cristina Bezzio, Lorenzo Bertani, Gian Paolo Caviglia, Marta Vernero, Angelo Armandi, Davide Giuseppe Ribaldone. Relapse Rates and Predictors for Relapse in Ulcerative Colitis and Crohn’s Disease Patients After Discontinuation of Vedolizumab or Ustekinumab: The REVEUS Study. Journal of Clinical Medicine 2025; 14(6): 1793 doi: 10.3390/jcm14061793